340B Use of Funds: A Call for Increased Transparency

August 142017340B Use of Funds: A Call for Increased Transparency

 

Jamila Seibel, PharmD, Consultant
Russ Barron, Consultant

At 340B Health’s annual Summer Coalition conference, a common theme appeared to emerge from both speakers and attendees alike in Washington DC: use of 340B funds. Over the last several months, a call for increased transparency of funds has surfaced in several areas of legislation ...

Read More

2017 340B Developments

May 12017A Recap of Important 2017 340B Developments

 

Jamila Seibel, PharmD, Consultant
With 5 months into the new year, we are almost halfway through 2017 already!  While postponement of the 340B “mega guidance” dominated headlines early in the year, there have been several noteworthy developments around the 340B program that should be heeded by covered entities ...

Read More

GAO Contract Pharmacy Study & Covered Entities

April 172017GAO 340B Contract Pharmacy Study: Time for Covered Entities to Take a Close Look at Contract Pharmacy Arrangements

Russ Barron, Associate Director

With the GAO's study of 340B contract pharmacies underway, covered entities should conduct a review of their contract pharmacy arrangements...

Read More

Ohio Medicaid Agency Holds Pharmacy Payment Changes Stakeholder Meeting Regarding CMS’s Covered Outpatient Drug Final Rule

January 232017Alinea’s 5 Key 340B Observations For 2017: HRSA Audits Intensify, Legislative Questions Linger, and New 340B Requirements Take Hold on April 1

Tim Olmstead, Managing Partner

Alinea outlines 5 key developments on upcoming legislation and insights gained from Alinea’s direct experience providing 340B audit and advisory services to clients across the nation ...

Read More

Ohio Medicaid Agency Holds Pharmacy Payment Changes Stakeholder Meeting Regarding CMS’s Covered Outpatient Drug Final Rule

December 152016Ohio Medicaid Agency Holds Pharmacy Payment Changes Stakeholder Meeting Regarding CMS’s Covered Outpatient Drug Final Rule

Jamila Seibel, PharmD, Consultant

On December 6, 2016, Ohio Medicaid, in conjunction with Mercer Government Human Services Consulting, held a stakeholder meeting to discuss changes to pharmacy payments for Medicaid patients in response to the Centers for Medicare and Medicaid Services’ (CMS) Covered Outpatient Drug Final Rule ...

Read More

340B Mega Guidance:  When will the new rules come to roost?  Or will they ever?

December 52016340B Mega Guidance: When will the new rules come to roost? Or will they ever?

Tim Olmstead, Managing Partner

In case your head was in the sand—and who can blame you with an unyielding budget season...Alinea has confirmed with several policy experts that the mega-guidance, scheduled to be released in December of 2016, will now be delayed ...

Read More

Coverd Entity Readiness: What's Around the Corner for 340B

September 192016Covered Entity Readiness: What's "Around the Corner" for 340B

Jamila Seibel, PharmD, Consultant

As a friendly reminder, several major developments in the 340B world that are currently taking place and should be closely monitored by all 340B ...

Read More

340B 2016 Manufacturer Summit - Alinea's 6 Key Takeaways:  The Manufacturers Viewpoint

Sepetmber 92016340B 2016 Manufacturer Summit - Alinea's 6 Key Takeaways: The Manufacturers Viewpoint

Shrujal Patel, Managing Partner

Bridging the Divide: This year's 340B Manufacturer Summit, hosted by CBI Net, provided an excellent forum for drug manufacturers to engage dialogue on ...

Read More

Provider Drug Diversion - Methodologies to Prevent Drug Diversion Pitfalls

July 102016Provider Drug Diversion - Methodologies to Prevent Drug Diversion Pitfalls

Tim Olmstead, Managing Partner

You've read the articles and guidelines from the CDC around opioid prescribing. You've studied federal and state requirements for risk mitigation and drilled ...

Read More

Medicare Part B Cuts for 340B Entities; What to be Ready for

March 12016Medicare Part B Cuts for 340B Entities; What to be Ready for

Tim Olmstead, Managing Partner

The recent news of MedPAC’s Vote in favor of a 10% reduction of Medicare Part B drug reimbursement for 340B entities has sent ripples through the safety ...

Read More

340B Coalition Winter Conference Promises Answers, But Uncertainty Still Lingers

February 202016340B Coalition Winter Conference Promises Answers, But Uncertainty Still Lingers

Russ Barron, Associate Director

On February 19th, the 340B Coalition wrapped up the 12th annual Winter Conference in San Diego. For many of the participants, the 3-day event ...

Read More

Final AMP Rule: Downstream Impact of AMP Rule Significant for 340B Covered Entities

January 152016Final AMP Rule: Downstream Impact of AMP Rule Significant for 340B Covered Entities

Keith Chop, Managing Partner

While the Final AMP Rule is generally seen as a positive for most stakeholders, as it increases transparency and may generate additional “voluntary” 340B ...

Read More

HRSA 340B Audit Findings:  The Dis-enrollment Question!

October 2015HRSA 340B Audit Findings: The Dis-enrollment Question!

Keith Chop, Managing Partner

At the 340B Health summer conference, we were asked multiple times if we knew of any covered entities that were asked to dis-enroll from the 340B program ...

Read More